Enrolment characteristics in age-related macular degeneration clinical trials: a cross-sectional study
- PMID: 39730975
- PMCID: PMC11978819
- DOI: 10.1038/s41433-024-03572-6
Enrolment characteristics in age-related macular degeneration clinical trials: a cross-sectional study
Abstract
Background/objectives: To investigate demographic enrolment characteristics in age-related macular degeneration (AMD) trials.
Subjects/methods: Clinicaltrials.gov was searched with "age-related macular degeneration" to identify RCTs with double, triple, or quadruple masking. Trial (e.g., study location, phase, masking, trial initiation year, and sponsor origin) and patient demographic data were collected. Sex-based AMD disease burdens were retrieved from the Global Burden of Disease database to calculate pooled female population-to-prevalence ratios (PPRs). Equitable trial enrolment was defined as PPR between 0.8-1.2. Demographic proportions were evaluated across trial characteristics using the Kruskal-Wallis test (alpha = 0.05) followed by post hoc comparisons. Secondary outcomes included absolute number of enrolled female, racial, and ethnic groups, and the association of trial characteristics with these demographics.
Results: We included 106 trials (77,939 patients; 46.3% female), spanning 1990-2020. The pooled female PRR was 0.88 (95% confidence interval [CI]: 0.82, 0.94). PPR values were inconclusive studies with quadruple blinding; phase I, III, IV, or not applicable status; foreign (non-US) site; US-only and foreign-only sponsor; and an initiation year before 2010. There was no significant difference in PPR between sublevels of analysed trial characteristics. Of the 74 (69.8%) trials that adequately detailed race, White participants comprised the largest group (N = 57,917; 82% of total participants). Thirty-seven (34.9%) trials adequately detailed ethnicity. The absolute enrolment of race and ethnic groups did not generally exhibit significant difference between sublevels of analysed trial characteristics.
Conclusions: Female enrolment was commensurate to their disease burden across all trial characteristics. Race and ethnicity were under-reported. Future trials should prioritise equitable study enrolment strategies.
© 2024. The Author(s), under exclusive licence to The Royal College of Ophthalmologists.
Conflict of interest statement
Competing interests: The authors declare no competing interests. Ethical approval: Under article 2.4 of the Tri-Council Policy Statement, institutional review board approval was waived since all data were sources from published primary research and publicly available registries. No identifiable information was generated by this work.
Similar articles
-
Diversity in enrollment to clinical trials for cataract medicine and surgery: meta-analysis.J Cataract Refract Surg. 2024 May 1;50(5):460-467. doi: 10.1097/j.jcrs.0000000000001395. J Cataract Refract Surg. 2024. PMID: 38237071
-
Antioxidant vitamin and mineral supplements for preventing age-related macular degeneration.Cochrane Database Syst Rev. 2017 Jul 30;7(7):CD000253. doi: 10.1002/14651858.CD000253.pub4. Cochrane Database Syst Rev. 2017. PMID: 28756617 Free PMC article.
-
Blue-light filtering intraocular lenses (IOLs) for protecting macular health.Cochrane Database Syst Rev. 2018 May 22;5(5):CD011977. doi: 10.1002/14651858.CD011977.pub2. Cochrane Database Syst Rev. 2018. PMID: 29786830 Free PMC article.
-
Antioxidant vitamin and mineral supplements for slowing the progression of age-related macular degeneration.Cochrane Database Syst Rev. 2017 Jul 31;7(7):CD000254. doi: 10.1002/14651858.CD000254.pub4. Cochrane Database Syst Rev. 2017. Update in: Cochrane Database Syst Rev. 2023 Sep 13;9:CD000254. doi: 10.1002/14651858.CD000254.pub5. PMID: 28756618 Free PMC article. Updated.
-
Statins for age-related macular degeneration.Cochrane Database Syst Rev. 2016 Aug 4;2016(8):CD006927. doi: 10.1002/14651858.CD006927.pub5. Cochrane Database Syst Rev. 2016. PMID: 27490232 Free PMC article.
References
-
- Lim LS, Mitchell P, Seddon JM, Holz FG, Wong TY. Age-related macular degeneration. Lancet. 2012;379:1728–38. - PubMed
MeSH terms
LinkOut - more resources
Full Text Sources
Medical